Evidence map›Paper›PMID 37323466›Full record

ArticleStatistics in biosciences2022

Targeted Search for Individualized Clinical Decision Rules to Optimize Clinical Outcomes.

Yanqing Wang, Yingqi Zhao, Yingye Zheng

Abstract read
In one paragraph

Article in Statistics in biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yanqing WangInstitute for Insight, Georgia State University, Atlanta, GA 30302.
Yingqi ZhaoPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.
Yingye ZhengPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
The Early Detection Research Network: Data Management and Coordinating CenterU24CA086368 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RUTH D ETZIONI, Ziding Feng · 2010 to 2026
$75.7M
EDRN--DATA MANAGEMENT AND COORDINATING CENTERU01CA086368 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI FENG, ZIDING · 2000 to 2010
$16.9M
Statistical Methods for Prospective Evaluation of BiomarkersR01CA236558 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ZHENG, YINGYE · 2019 to 2024
$1.9M
Statistical methods for healthcare in complex patients with diabetesR01DK108073 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ZHAO, YINGQI · 2015 to 2019
$1.5M
Evaluation of commercially available prostate cancer assays to accelerate novel applications in active surveillanceUH3CA234196 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LIN, DANIEL W., ZHENG, YINGYE · 2019 to 2021
$1.0M
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
Childhood obesity surveillance using electronic health records dataR21HD086754 · NICHD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ZHAO, YINGQI · 2016 to 2017
$494k
NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA236558NCI NIH HHS U01 CA086368NCI NIH HHS U24 CA086368NCI NIH HHS UH3 CA234196NICHD NIH HHS R21 HD086754NIDDK NIH HHS R01 DK108073NIH HHS S10 OD020069
6 · The paper itself

Abstract

Novel biomarkers, in combination with currently available clinical information, have been sought to enhance clinical decision making in many branches of medicine, including screening, surveillance and prognosis. An individualized clinical decision rule (ICDR) is a decision rule that matches subgroups of patients with tailored medical regimen based on patient characteristics. We proposed new approaches to identify ICDRs by directly optimizing a risk-adjusted clinical benefit function that acknowledges the tradeoff between detecting disease and over-treating patients with benign conditions. In particular, we developed a novel plug-in algorithm to optimize the risk-adjusted clinical benefit function, which leads to the construction of both nonparametric and linear parametric ICDRs. In addition, we proposed a novel approach based on the direct optimization of a smoothed ramp loss function to further enhance the robustness of a linear ICDR. We studied the asymptotic theories of the proposed estimators. Simulation results demonstrated good finite sample performance for the proposed estimators and improved clinical utilities when compared to standard approaches. The methods were applied to a prostate cancer biomarker study.

Indexed as

BiomarkerFalse positive fractionMachine LearningTrue positive fraction

Identifiers

PMID37323466
PMCPMC10270673

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.